ВУДВАРД Дэвид Ф. (US),ХЕЙДЕЛБАУ Тод М. (US),СТАМЕР В. Дэниел (US)
申请号：
RU2013147049/15
公开号：
RU2013147049A
申请日:
2012.03.26
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. An aqueous ophthalmic composition comprising an S1P antagonist and at least one compound selected from the group consisting of β-blockers, adrenergic agonists, non-selective adrenergic agonists, α-selective adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, direct-acting cholinergic agonists, cholinesterase inhibitors, glutamate antagonists, Ca-channel blockers, prostamides, prostaglandins, cannabinoids, muscarinic agents, and combinations thereof. 2. The composition according to claim 1, characterized in that the S1P antagonist is an S1P2.3 antagonist. A composition according to claim 1, characterized in that said compound is a prostamide or prostaglandin. The composition according to claim 3, characterized in that the prostamide or prostaglandin is an EPI or EP.5 agonist. The composition according to claim 3, characterized in that the prostamide or prostaglandin is bimatoprost, latanoprost or travoprost. The composition of claim 1, wherein the compound is a β-blocker, an adrenergic agonist, a non-selective adrenergic agonist, or an α-selective adrenergic agonist. A composition according to claim 1, characterized in that said compound is a muscarinic agent. The composition according to claim 7, characterized in that the muscarinic agent is pilocarpine. The composition of claim 1, wherein said compound is a carbonic anhydrase inhibitor. A method of lowering IOP in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a composition according to claim 11. A way to further reduce IOP in p�1. Водная глазная композиция, включающая антагонист S1P и по меньшей мере одно соединение, выбранное из группы, состоящей из β-блокаторов, адренергических агонистов, неселективных адренергических агонистов, α-селективных адренергических агонистов, ингибиторов карбоангидразы, холинергических агонистов, холинергических агонистов прямого действия, ингибиторов холинэстеразы, глутаматных антагонистов, блокаторов
